↓ Skip to main content

Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts

Overview of attention for article published in Investigational New Drugs, November 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
2 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
57 Mendeley
Title
Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts
Published in
Investigational New Drugs, November 2015
DOI 10.1007/s10637-015-0303-x
Pubmed ID
Authors

Jeffrey D. Serrill, Xuemei Wan, Andrew M. Hau, Hyo Sang Jang, Daniel J. Coleman, Arup K. Indra, Adam W. G. Alani, Kerry L. McPhail, Jane E. Ishmael

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Germany 1 2%
Unknown 55 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 30%
Student > Master 6 11%
Researcher 6 11%
Student > Bachelor 5 9%
Professor > Associate Professor 3 5%
Other 7 12%
Unknown 13 23%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 10 18%
Agricultural and Biological Sciences 9 16%
Medicine and Dentistry 8 14%
Chemistry 6 11%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Other 6 11%
Unknown 16 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2016.
All research outputs
#8,059,753
of 26,017,215 outputs
Outputs from Investigational New Drugs
#345
of 1,286 outputs
Outputs of similar age
#93,100
of 296,045 outputs
Outputs of similar age from Investigational New Drugs
#4
of 11 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,286 research outputs from this source. They receive a mean Attention Score of 5.0. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,045 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.